French Actos risk not seen with other diabetes drugs, and only in bladder cancer
This article was originally published in Scrip
Not long after the furore over its tardy withdrawal of Servier's antidiabetic Mediator, the French medicines regulator Afssaps has now said it will suspend Takeda's diabetes drugs Actos and Competact, both formulated with pioglitazone. The move follows results of a French study indicating an increased risk of bladder cancer but comes before the European Medicines Agency has concluded its own benefit:risk review of the drugs. The Japanese drug regulator had not taken any action over Actos by close of business on 10 June, but Germany's Federal Institute for Drugs and Medical Devices has announced that it has suspended the use of the drug.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.